efficacy
Singulair v. Steroids
Observation: children with mild to moderate acute asthma had been stabilized in the ER; upon discharge they received montelukast (Singulair] or oral prednisolone; those receiving the latter, the oral corticosteroids after discharge did better.
Osteoarthritis of the Knee: Treatments That Lack Benefit
Three Treatments for Osteoarthritis of the Knee: Evidence Shows Lack of Benefit Clinician Summary Guide published 8 Apr 2009
The Managed Care-Pharma Interface-Part IV: Post-Marketing Facilitation
Raymond V. Gilmartin, the former Chairman, President and Chief Executive Officer of Merck & Co., Inc. (1994-2005) in a speech January 19, 2000 gave commentary about the Pharmaceutical and Medicine Manufacturing (PMM) industry that I continue to dissect (See "Part III: the Pitfalls and the Promise" (last week). My objective is to get to synergism between the PMM industry and health care: (Cont'd)
The Managed Care-Pharma Interface-Part II: the Tension
As stated in the inaugural issue of this blog, the interface between managed care and the Pharmaceutical and Medicine Manufacturing (PMM) industries, is vital. They have in common the issues of appropriateness, compliance, cost-effectiveness, patient selection and symbiosis among all relevant players on the health care stage (ACCESS).
I say, put the practicing clinician on the PMM team and visa versa—How and Why?
